Journals / Medicine Science / 2017 / Cilt: 6 - Sayı: 2

Erythropoietin hyporesponsiveness among egyptian hemodialysis patients

Pages
285–298
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Hepcidin did not show any correlations with IL-6 or CRP, so inflammatory mediators did not influence its high level, but mostly due to its retention in ESRD patients

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Almost all ESRD patients on HD receive iron and EPO to treat anemia, however some patients do not respond sufficiently to the therapy.
📊
Key Findings & Data:Response to EPO influenced by various factors, such as malnutrition, vitamin deficiencies, chronic blood loss, secondary hyperparathyroidism, chronic inflammation and decrease hepcidin excretion.
💡
Conclusion & Impact:Hepcidin did not show any correlations with IL-6 or CRP, so inflammatory mediators did not influence its high level, but mostly due to its retention in ESRD patients
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Almost all ESRD patients on HD receive iron and EPO to treat anemia, however some patients do not respond sufficiently to the therapy. Response to EPO influenced by various factors, such as malnutrition, vitamin deficiencies, chronic blood loss, secondary hyperparathyroidism, chronic inflammation and decrease hepcidin excretion. This study included 80 anemic patients who had been on regular HD for more than 3 months. Patients received adequate doses of ESA and iron for 3 months, after that they were classified into two groups ESA responders and ESA hyporesponders. Laboratory investigations were done to assess some of risk factors which may lead to ESA hyporesponsiveness as Iron profile, IL-6, CRP, anti-EPO antibody, hepcidin level and PTH. Sixty percent of the patients were EPO hypo-responsive; ferritin has higher level in hypo-responders. Hepcidin and IL-6 markedly elevated among ESRD patients also were markedly elevated among hypo-responders. Hepcidin did not show any correlations with IL-6 or CRP but has strong correlation with ferritin. Prevalence of anti-EPO antibody was 7.5 % of total population. Parathyroid hormone had no statistically significant association with HB or reticulocytes. Hepcidin was higher among EPO-hyporesponders and had strong correlation with ferritin, so we can consider hepcidin as an important biomarker for iron stores utilization in anemic patients and to predict patient response to EPO therapy. Hepcidin did not show any correlations with IL-6 or CRP, so inflammatory mediators did not influence its high level, but mostly due to its retention in ESRD patients

🔖

Cite This Article

PHD, M. M. A., ZAKİ, H. M., MSC, M. (2017). Erythropoietin hyporesponsiveness among egyptian hemodialysis patients. Medicine Science, Cilt: 6 - Sayı: 2, 285–298. https://ajindex.com/articles/277888

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the third national health and nutrition examination survey. J Am Soc Nephrol. 2002;13(2):504-10
  2. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J.Association of kidney function with anemia: the third national health and nutrition examination survey (1988-1994). Arch Intern Med. 2002;162(12):1401-8
  3. Kamath S, Prabhu RA, Patil A. Prevalence of anemia in patients undergoing maintenance hemodialysis. Manipal University, India. Int J Clin Surg Adv. 2013;1(2):16-21
  4. El-Shahed AM, Sharf SA, El-Sebaee HA. Hemoglobin level, associated co-morbidities and quality of life among patients undergoing hemodialysis at one of the university hospitals in cairo governorate. Wasj. 2013;23(1):29-36
  5. Foley RN, Curtis BM, Parfrey PS. Erythropoietin therapy, hemoglobin targets and quality of life in healthy hemodialysis patients: a randomized trial. Clin J Am Soc Nephrol. 2009;4(4):726- 33
  6. Hodges VM, Rainey S, Lappin TR, Maxwell AP. Pathophysiology of anemia and erythrocytosis. Crit Rev Oncol Hematol. 2007;64(2):139- 58
  7. Anees MF, Hameed A, Mumtaz M Ibrahim M, Saeed Khan MN. Dialysis-related a factors affecting quality of life in patients on. hemodialysis. Iran J Kidney Dis. 2011;5(1): 9-14
  8. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease.2012; 2: 288-310
  9. Priyadarshi A, Shapiro JI. Erythropoietin resistance in the treatment of the anemia of chronic renal failure. Semin Dial. 2006;19(4):273-8
  10. De Lurdes Agostinho Cabrita de Lurdes Agostinho Cabrita A, Pinho A, Malho A, Morgado E, Faísca M, Carrasqueira H, Silva AP, Neves PL. Risk factors for high erythropoiesis stimulating agent resistance index in pre-dialysis chronic kidney disease patients, stages 4 and 5. Int Urol Nephrol. 2011;43(3):835-40
  11. Costa E, Lima M, Alves JM, Rocha S, Rocha‐Pereira P, Castro E, Miranda V, do SF, Loureiro A, Quintanilha A, Belo L, Santos‐Silva A. Inflammation, T-cell phenotype, and inflammatory cytokines in chronic kidney disease patients under hemodialysis and its rela‐ tionship to resistance to recombinant human erythropoietin therapy. J Clin Immunol. 2008;28(3):268-75
  12. Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: Implications for the anemia of CKD. Am J Kidney Dis. 2010;55(4):726-41
  13. Park CH, Valore E